🗣️ Matthew Strickland, MD, discusses phase IIb TERRIFIC data evaluating neoadjuvant tislelizumab + chemoradiotherapy vs chemo(radio)therapy for patients with locally advanced gastric/GEJ adenocarcinoma.
🎥 Watch the video: https://ow.ly/LcNf50Y7JNK
🎥 Watch the video: https://ow.ly/LcNf50Y7JNK
February 2, 2026 at 8:30 PM
🗣️ Matthew Strickland, MD, discusses phase IIb TERRIFIC data evaluating neoadjuvant tislelizumab + chemoradiotherapy vs chemo(radio)therapy for patients with locally advanced gastric/GEJ adenocarcinoma.
🎥 Watch the video: https://ow.ly/LcNf50Y7JNK
🎥 Watch the video: https://ow.ly/LcNf50Y7JNK
Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal #Cancer (TACTIC CRC-02): a phase II study. www.esmoopen.com/article/S205...
Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study
The TACTIC CRC-02 study evaluated the efficacy and safety of tislelizumab, a humanized
immunoglobulin G4 monoclonal antibody targeting programmed cell death protein 1, combined
with standard XELOX plu...
www.esmoopen.com
January 29, 2026 at 12:57 PM
Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal #Cancer (TACTIC CRC-02): a phase II study. www.esmoopen.com/article/S205...
#Neoadjuvant #tislelizumab plus nab‑paclitaxel and #anthracycline‑based #chemotherapy achieved 68.2% pCR and 93.2% ORR in #TNBC, while #multiomics profiling revealed immune pathway enrichment and CDKN1A+CD8 T cells linked to response.
#OpenAccess in #STTT: doi.org/10.1038/s413...
#OpenAccess in #STTT: doi.org/10.1038/s413...
January 18, 2026 at 10:01 AM
#Neoadjuvant #tislelizumab plus nab‑paclitaxel and #anthracycline‑based #chemotherapy achieved 68.2% pCR and 93.2% ORR in #TNBC, while #multiomics profiling revealed immune pathway enrichment and CDKN1A+CD8 T cells linked to response.
#OpenAccess in #STTT: doi.org/10.1038/s413...
#OpenAccess in #STTT: doi.org/10.1038/s413...
Zanidatamab Plus Chemo With/Without Tislelizumab Yields Unprecedented PFS/OS Outcomes in HER2+ Gastroesophageal Adenocarcinoma
Lead author Elena Elimova, MD, details the implications of findings from HERIZON-GEA-01 trial shared at ASCO #GI26 www.onclive.com/view/zanidat...
Lead author Elena Elimova, MD, details the implications of findings from HERIZON-GEA-01 trial shared at ASCO #GI26 www.onclive.com/view/zanidat...
Zanidatamab Plus Chemo With/Without Tislelizumab Yields Unprecedented PFS/OS Outcomes in HER2+ Gastroesophageal Adenocarcinoma | OncLive
Elena Elimova, MD, discusses findings for zanidatamab chemotherapy with/without tislelizumab in advanced HER2-positive gastroesophageal adenocarcinoma.
www.onclive.com
January 16, 2026 at 3:46 PM
Zanidatamab Plus Chemo With/Without Tislelizumab Yields Unprecedented PFS/OS Outcomes in HER2+ Gastroesophageal Adenocarcinoma
Lead author Elena Elimova, MD, details the implications of findings from HERIZON-GEA-01 trial shared at ASCO #GI26 www.onclive.com/view/zanidat...
Lead author Elena Elimova, MD, details the implications of findings from HERIZON-GEA-01 trial shared at ASCO #GI26 www.onclive.com/view/zanidat...
🔬Median OS reached 26.4 months with the zanidatamab + tislelizumab regimen, supporting its potential as a new first-line standard of care.
🔗 Read more: bit.ly/ONCOnews09J-02
#ONCOnews #OncoAlert #OncEd #GastroesophagealCancer #Oncology #ClinicalTrials #TargetedTherapy #Immunotherapy
🔗 Read more: bit.ly/ONCOnews09J-02
#ONCOnews #OncoAlert #OncEd #GastroesophagealCancer #Oncology #ClinicalTrials #TargetedTherapy #Immunotherapy
January 9, 2026 at 1:00 PM
🔬Median OS reached 26.4 months with the zanidatamab + tislelizumab regimen, supporting its potential as a new first-line standard of care.
🔗 Read more: bit.ly/ONCOnews09J-02
#ONCOnews #OncoAlert #OncEd #GastroesophagealCancer #Oncology #ClinicalTrials #TargetedTherapy #Immunotherapy
🔗 Read more: bit.ly/ONCOnews09J-02
#ONCOnews #OncoAlert #OncEd #GastroesophagealCancer #Oncology #ClinicalTrials #TargetedTherapy #Immunotherapy
🚨 Breaking GI Oncology Update!
📊 Phase III HERIZON-GEA-01: Zanidatamab + chemotherapy, with or without tislelizumab, significantly improved Progression-Free Survival (PFS) and Overall Survival (OS) versus trastuzumab-based therapy in HER2-positive advanced gastroesophageal adenocarcinoma (GEA).
📊 Phase III HERIZON-GEA-01: Zanidatamab + chemotherapy, with or without tislelizumab, significantly improved Progression-Free Survival (PFS) and Overall Survival (OS) versus trastuzumab-based therapy in HER2-positive advanced gastroesophageal adenocarcinoma (GEA).
January 9, 2026 at 1:00 PM
🚨 Breaking GI Oncology Update!
📊 Phase III HERIZON-GEA-01: Zanidatamab + chemotherapy, with or without tislelizumab, significantly improved Progression-Free Survival (PFS) and Overall Survival (OS) versus trastuzumab-based therapy in HER2-positive advanced gastroesophageal adenocarcinoma (GEA).
📊 Phase III HERIZON-GEA-01: Zanidatamab + chemotherapy, with or without tislelizumab, significantly improved Progression-Free Survival (PFS) and Overall Survival (OS) versus trastuzumab-based therapy in HER2-positive advanced gastroesophageal adenocarcinoma (GEA).
Zanidatamab Plus Chemo ± Tislelizumab May Replace First-Line Standard of Care in HER2+ Gastroesophageal Adenocarcinoma @ascocancer.bsky.social #GI26 #esocsm #oncology
www.onclive.com/view/zanidat...
www.onclive.com/view/zanidat...
Zanidatamab Plus Chemo ± Tislelizumab May Replace First-Line Standard of Care in HER2+ Gastroesophageal Adenocarcinoma | OncLive
HERIZON-GEA-01 is the first phase 3 study to demonstrate a median PFS greater than 1 year, and a median OS greater than 2 years in metastatic GEA.
www.onclive.com
January 8, 2026 at 11:10 PM
Zanidatamab Plus Chemo ± Tislelizumab May Replace First-Line Standard of Care in HER2+ Gastroesophageal Adenocarcinoma @ascocancer.bsky.social #GI26 #esocsm #oncology
www.onclive.com/view/zanidat...
www.onclive.com/view/zanidat...
New research from #GI26: Zanidatamab and chemo, +/- tislelizumab, can slow cancer growth and help people with #HER2-positive metastatic gastroesophageal adenocarcinoma live longer.
Learn more: brnw.ch/21wYVAi
Learn more: brnw.ch/21wYVAi
January 8, 2026 at 4:43 PM
New research from #GI26: Zanidatamab and chemo, +/- tislelizumab, can slow cancer growth and help people with #HER2-positive metastatic gastroesophageal adenocarcinoma live longer.
Learn more: brnw.ch/21wYVAi
Learn more: brnw.ch/21wYVAi
🚨New Oncology Update!
🔔 ZIIHERA® (zanidatamab) + TEVIMBRA® (tislelizumab) + chemotherapy showed compelling survival and disease control versus the current standard in first-line HER2+ advanced gastroesophageal adenocarcinoma (GEA), regardless of PD-L1 status.
🔔 ZIIHERA® (zanidatamab) + TEVIMBRA® (tislelizumab) + chemotherapy showed compelling survival and disease control versus the current standard in first-line HER2+ advanced gastroesophageal adenocarcinoma (GEA), regardless of PD-L1 status.
January 7, 2026 at 3:00 PM
🚨New Oncology Update!
🔔 ZIIHERA® (zanidatamab) + TEVIMBRA® (tislelizumab) + chemotherapy showed compelling survival and disease control versus the current standard in first-line HER2+ advanced gastroesophageal adenocarcinoma (GEA), regardless of PD-L1 status.
🔔 ZIIHERA® (zanidatamab) + TEVIMBRA® (tislelizumab) + chemotherapy showed compelling survival and disease control versus the current standard in first-line HER2+ advanced gastroesophageal adenocarcinoma (GEA), regardless of PD-L1 status.
Overcoming Acquired PD-1 Resistance in NSCLC: Tislelizumab + Sitravatinib + Docetaxel
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #LungCancer #Tislelizumab #Sitravatinib #Docetaxel
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #LungCancer #Tislelizumab #Sitravatinib #Docetaxel
Overcoming Acquired PD-1 Resistance in NSCLC: Tislelizumab + Sitravatinib + Docetaxel - OncoDaily
Phase II study explores tislelizumab, sitravatinib, and docetaxel to overcome acquired PD-1 resistance in advanced NSCLC with immune remodeling signals.
oncodaily.com
December 29, 2025 at 7:58 PM
Overcoming Acquired PD-1 Resistance in NSCLC: Tislelizumab + Sitravatinib + Docetaxel
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #LungCancer #Tislelizumab #Sitravatinib #Docetaxel
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #NSCLC #LungCancer #Tislelizumab #Sitravatinib #Docetaxel
#Article in #MedComm
A Phase II Study of #Sitravatinib Combined With #Tislelizumab Plus Docetaxel for Acquired #Resistance to PD-(L)1 in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer doi.org/10.1002/mco2...
#AcquiredResistance #Tcell #immunotherapy #PSI #TCR
A Phase II Study of #Sitravatinib Combined With #Tislelizumab Plus Docetaxel for Acquired #Resistance to PD-(L)1 in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer doi.org/10.1002/mco2...
#AcquiredResistance #Tcell #immunotherapy #PSI #TCR
A Phase II Study of Sitravatinib Combined With Tislelizumab Plus Docetaxel for Acquired Resistance to PD‐(L)1 in Patients With Advanced/Metastatic Non‐Small Cell Lung Cancer
Over 60% of NSCLC patients treated with immune checkpoint inhibitors (ICIs) develop acquired resistance (AR). This study demonstrates that combining tislelizumab, sitravatinib, and docetaxel achieves...
doi.org
December 26, 2025 at 1:36 AM
#Article in #MedComm
A Phase II Study of #Sitravatinib Combined With #Tislelizumab Plus Docetaxel for Acquired #Resistance to PD-(L)1 in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer doi.org/10.1002/mco2...
#AcquiredResistance #Tcell #immunotherapy #PSI #TCR
A Phase II Study of #Sitravatinib Combined With #Tislelizumab Plus Docetaxel for Acquired #Resistance to PD-(L)1 in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer doi.org/10.1002/mco2...
#AcquiredResistance #Tcell #immunotherapy #PSI #TCR
Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative #BreastCancer: a multicenter, open-label, phase II cTRIO study. www.thelancet.com/journals/ecl...
Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study
Despite being a de-escalating and anthracycline-free neoadjuvant treatment approach,
the triplet combination therapy showed promising efficacy and safety, signifying a
crucial step toward the optimiza...
www.thelancet.com
December 18, 2025 at 11:35 AM
Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative #BreastCancer: a multicenter, open-label, phase II cTRIO study. www.thelancet.com/journals/ecl...
Peri-operative Tislelizumab + Neoadjuvant Chemotherapy in Resectable NSCLC: Final RATIONALE-315 Results
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Peri-operative Tislelizumab + Neoadjuvant Chemotherapy in Resectable NSCLC: Final RATIONALE-315 Results - OncoDaily
Peri-operative tislelizumab plus platinum chemotherapy significantly improved OS, EFS, and pathological response in resectable stage II–IIIA NSCLC in RATIONALE-315.
oncodaily.com
December 7, 2025 at 9:18 PM
Peri-operative Tislelizumab + Neoadjuvant Chemotherapy in Resectable NSCLC: Final RATIONALE-315 Results
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell #LungCancer: final analysis of the randomized RATIONALE-315 trial. www.annalsofoncology.org/article/S092...
Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial
Peri-operative immunotherapy, particularly anti-programmed cell death protein-1 therapy,
combined with neoadjuvant chemotherapy has emerged as one of the standard-of-care
options for resectable non-sm...
www.annalsofoncology.org
December 4, 2025 at 12:43 PM
Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell #LungCancer: final analysis of the randomized RATIONALE-315 trial. www.annalsofoncology.org/article/S092...
ZSAB-TOP, a phase 2 trial of first-line #Tislelizumab + Ociperlimab with GemCis in advanced #BiliaryTractCancer (BTC), shows encouraging tumor responses, survival outcomes, and a manageable safety profile. @fudan-university.bsky.social
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
November 26, 2025 at 10:30 PM
ZSAB-TOP, a phase 2 trial of first-line #Tislelizumab + Ociperlimab with GemCis in advanced #BiliaryTractCancer (BTC), shows encouraging tumor responses, survival outcomes, and a manageable safety profile. @fudan-university.bsky.social
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
Tislelizumab + Chemotherapy in #Gastric #Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up link.springer.com/article/10.1... #hvhebron #onco [Text complet]
Tislelizumab + Chemotherapy in Gastric Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up - Advances in Therapy
Introduction Tislelizumab + chemotherapy has shown promising results as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJC). We present long-term safety and ef...
link.springer.com
November 20, 2025 at 3:37 PM
Tislelizumab + Chemotherapy in #Gastric #Cancer: Long-Term RATIONALE-305 Randomized Trial Follow-up link.springer.com/article/10.1... #hvhebron #onco [Text complet]
🚨Latest: Phase III results!
📣 Phase 3 results show ZIIHERA® (zanidatamab) delivers strong efficacy as a leading HER2-targeted therapy.
✅ Its combination with TEVIMBRA® (tislelizumab) + chemotherapy is emerging as a new first-line standard of care in HER2-positive gastroesophageal cancer.
📣 Phase 3 results show ZIIHERA® (zanidatamab) delivers strong efficacy as a leading HER2-targeted therapy.
✅ Its combination with TEVIMBRA® (tislelizumab) + chemotherapy is emerging as a new first-line standard of care in HER2-positive gastroesophageal cancer.
November 18, 2025 at 12:30 PM
🚨Latest: Phase III results!
📣 Phase 3 results show ZIIHERA® (zanidatamab) delivers strong efficacy as a leading HER2-targeted therapy.
✅ Its combination with TEVIMBRA® (tislelizumab) + chemotherapy is emerging as a new first-line standard of care in HER2-positive gastroesophageal cancer.
📣 Phase 3 results show ZIIHERA® (zanidatamab) delivers strong efficacy as a leading HER2-targeted therapy.
✅ Its combination with TEVIMBRA® (tislelizumab) + chemotherapy is emerging as a new first-line standard of care in HER2-positive gastroesophageal cancer.
Zanidatamab Plus Chemo ± Tislelizumab Impresses in HER2+ Gastroesophageal Adenocarcinoma #GIcancer #oncology
www.onclive.com/view/zanidat...
www.onclive.com/view/zanidat...
Zanidatamab Plus Chemo ± Tislelizumab Impresses in HER2+ Gastroesophageal Adenocarcinoma | OncLive
Zanidatamab-based regimens improved PFS and OS vs chemotherapy in HER2+ gastroesophageal adenocarcinoma, positioning the agent as a potential new standard.
www.onclive.com
November 17, 2025 at 5:32 PM
Zanidatamab Plus Chemo ± Tislelizumab Impresses in HER2+ Gastroesophageal Adenocarcinoma #GIcancer #oncology
www.onclive.com/view/zanidat...
www.onclive.com/view/zanidat...
The NATIC trial, evaluating #Neoadjuvant anti-PD-1 #Tislelizumab + #Chemotherapy in treatment-naïve stage IB3/IIA2 LACC patients, showed promising #Antitumor efficacy and a tolerable safety profile. #medsky
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
November 14, 2025 at 11:01 AM
The NATIC trial, evaluating #Neoadjuvant anti-PD-1 #Tislelizumab + #Chemotherapy in treatment-naïve stage IB3/IIA2 LACC patients, showed promising #Antitumor efficacy and a tolerable safety profile. #medsky
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
Adding the #PD1antibody #tislelizumab to perioperative SOX #chemotherapy in locally advanced #GastroesophagealJunctionAdenocarcinoma achieved high pathological response & R0 resection rates with manageable safety, supporting its therapeutic potential.
#STTT: doi.org/10.1038/s413...
#STTT: doi.org/10.1038/s413...
November 4, 2025 at 11:02 AM
Adding the #PD1antibody #tislelizumab to perioperative SOX #chemotherapy in locally advanced #GastroesophagealJunctionAdenocarcinoma achieved high pathological response & R0 resection rates with manageable safety, supporting its therapeutic potential.
#STTT: doi.org/10.1038/s413...
#STTT: doi.org/10.1038/s413...
The NATIC trial, evaluating #Neoadjuvant anti-PD-1 #Tislelizumab + #Chemotherapy in treatment-naïve stage IB3/IIA2 LACC patients, showed promising #Antitumor efficacy and a tolerable safety profile. #medsky
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
November 2, 2025 at 10:45 AM
The NATIC trial, evaluating #Neoadjuvant anti-PD-1 #Tislelizumab + #Chemotherapy in treatment-naïve stage IB3/IIA2 LACC patients, showed promising #Antitumor efficacy and a tolerable safety profile. #medsky
#STTT #OpenAccess: doi.org/10.1038/s413...
#STTT #OpenAccess: doi.org/10.1038/s413...
Porustobart Plus Tislelizumab Yields Promising Responses in Pretreated MSS mCRC #crcsm #oncology www.onclive.com/view/porusto...
Porustobart Plus Tislelizumab Yields Promising Responses in Pretreated MSS mCRC | OncLive
The phase 2 trial of porustobart plus tislelizumab showed antitumor activity and manageable safety in heavily pretreated MSS metastatic colorectal cancer.
www.onclive.com
October 23, 2025 at 3:36 PM
Porustobart Plus Tislelizumab Yields Promising Responses in Pretreated MSS mCRC #crcsm #oncology www.onclive.com/view/porusto...
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell #LungCancer (HARMONi-6): a randomised, double-blind, phase 3 trial. www.thelancet.com/journals/lan...
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
In patients with untreated advanced squamous NSCLC, ivonescimab plus chemotherapy
showed significantly improved progression-free survival compared with tislelizumab
plus chemotherapy, regardless of PD...
www.thelancet.com
October 23, 2025 at 1:22 PM
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell #LungCancer (HARMONi-6): a randomised, double-blind, phase 3 trial. www.thelancet.com/journals/lan...
Harbour BioMed Reports Promising Phase II Study Outcomes of HBM4003 with Tislelizumab for mCRC Treatment#None#Harbour_BioMed#Tislelizumab#HBM4003
Harbour BioMed Reports Promising Phase II Study Outcomes of HBM4003 with Tislelizumab for mCRC Treatment
Harbour BioMed reveals encouraging Phase II results for HBM4003 combined with tislelizumab in patients with MSS mCRC, showcasing potential in novel treatments.
third-news.com
October 23, 2025 at 12:12 AM
Harbour BioMed Reports Promising Phase II Study Outcomes of HBM4003 with Tislelizumab for mCRC Treatment#None#Harbour_BioMed#Tislelizumab#HBM4003
Preliminary results from a phase 2 study suggest that the combination of tislelizumab with chidamide, lenalidomide, and etoposide may be effective for the treatment of R/R ENKTL. Presented at #ESMO25.
https://bit.ly/4ovkEGT
#lymsm
https://bit.ly/4ovkEGT
#lymsm
Combination Therapy With Tislelizumab May Be Effective in ENKTL - Hematology Advisor
Researchers sought to determine whether combination therapy with tislelizumab would be effective in treating patients with ENKTL.
bit.ly
October 22, 2025 at 4:21 PM
Preliminary results from a phase 2 study suggest that the combination of tislelizumab with chidamide, lenalidomide, and etoposide may be effective for the treatment of R/R ENKTL. Presented at #ESMO25.
https://bit.ly/4ovkEGT
#lymsm
https://bit.ly/4ovkEGT
#lymsm